EFFECT OF TAMOXIFEN ON LIPID PROFILE IN IRAQI BREAST CANCER WOMEN.

Background: Tamoxifen-citrate, a non-steroidal anti-estrogen, is one of the most widely used hormonal treatments for patients with breast cancer. It has been suggested that its estrogenic activity is mainly responsible for the observed changes in lipid parameters. Objective: the aim of this study is to explore the effects of tamoxifen on lipid profile in women with breast cancer. Patients and Methods: the present study is a cross-sectional study (2010/2011) done at Al-Yarmouk Teaching Hospital. Includes measurement of LP in sera of postmenopausal women with BC (whether newly diagnosed or on tamoxifen treatment). This measurement was done using colorimetric method. In The results of this study include a total of 200 patients with BC were involved in this study, they were classified as newly diagnosed postmenopausal women with BC G1: (n=100); Postmenopausal women with BC on tamoxifen therapy G2: (n=100). Results: Serum Lipid Profile: Serum LP was significantly improved in BC group who receive treatment with tamoxifen when compared with newly diagnosed BC groups whom receive no therapy : this improvement was in term of significant reduction in TC, TG, LDL and VLDL (despite the reduction was insignificant) accompanied by elevation of HDL although it was insignificant. Conclusion: the level of LP was significantly improved upon tamoxifen treatment.